A 29-year-old woman with type 1 diabetes mellitus on mealtime insulin lispro presents with persistent postprandial glucose excursions peaking at 280 mg/dL despite carbohydrate counting. Vital signs: BP 118/76, HR 88, RR 16, temp 37°C, SpO2 98%. HbA1c is 8.2%, and fasting C-peptide is undetectable, confirming absent endogenous insulin secretion. Physical exam reveals no abdominal tenderness or distension. Her endocrinologist adds a subcutaneous amylin analog administered before meals that decreases glucagon secretion and slows gastric emptying. She denies nausea or gastrointestinal symptoms. Which of the following drugs was most likely added?
- A)Semaglutide
- B)Metformin
- C)Repaglinide
- D)PramlintideGABARITO
- E)Sitagliptin
Explicação
Pramlintide is an amylin analog that decreases glucagon release and slows gastric emptying, thereby reducing postprandial glucose spikes. It is used as adjunctive therapy in insulin treated diabetes and can increase hypoglycemia risk if insulin is not adjusted... Ver explicação completa e trilha adaptativa →